Recent Company News

• 06:14 AM ET Apr 08, 2026
  

  Shionogi & Co. reinstated neutral at Goldman Sachs (¥3606.0000, 0)

• 12:20 AM ET Apr 08, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (72 total)

• 11:13 PM ET Apr 07, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (111 total)

• 07:34 PM ET Apr 01, 2026
  

  Shionogi & Co. completes acquisition of global rights to RADICAVA (¥3627.0000, 0)

• 02:06 AM ET Apr 01, 2026
  

  GSK and Shionogi & Co., Ltd further to their announcements on 20-Jan-26, announce the completion of the transaction for the 11.7% economic interest in ViiV Healthcare Limited

• 07:38 PM ET Mar 23, 2026
  

  Shionogi & Co. to acquire remaining 50% stake in Shionogi-Apnimed Sleep Science for $100M (¥15.95B) from JV partner Apnimed (¥3256.0000, 0)

• 02:03 AM ET Mar 23, 2026
  

  Shionogi & Co. receives approval in Japan for expanded indication of XOCOVA for post-exposure prophylaxis of COVID-19 (¥3256.0000, -111)

• 08:56 AM ET Mar 19, 2026
  

  Shionogi announces start of global phase 2 trial in LOPD (¥3367.0000, 0)

• 02:09 PM ET Feb 25, 2026
  

  Viiv announces 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study

• 02:04 PM ET Feb 25, 2026
  

  Viiv announces data from Phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV